65 related articles for article (PubMed ID: 21442199)
41. Better characterization of vinflunine pharmacokinetics variability and exposure/toxicity relationship to improve its use: Analyses from 18 trials.
Schmitt A; Nguyen L; Zorza G; Ferré P; Pétain A
Br J Clin Pharmacol; 2018 May; 84(5):900-910. PubMed ID: 29341179
[TBL] [Abstract][Full Text] [Related]
42. A phase I clinical and pharmacokinetic study evaluating vinflunine in combination with epirubicin as first-line treatment in metastatic breast cancer.
Chan S; Campone M; Santoro A; Conte PF; Bostnavaron M; Nguyen L
Cancer Chemother Pharmacol; 2014 May; 73(5):903-10. PubMed ID: 24627219
[TBL] [Abstract][Full Text] [Related]
43. A phase I study of vinflunine in combination with capecitabine in patients with metastatic breast cancer previously treated with anthracyclines and taxanes.
Campone M; Isambert N; Bourbouloux E; Roché H; Bonneterre J; Milano G; Fumoleau P
Cancer Chemother Pharmacol; 2012 Apr; 69(4):871-9. PubMed ID: 22045498
[TBL] [Abstract][Full Text] [Related]
44. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL
Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
[TBL] [Abstract][Full Text] [Related]
45. Liposomal pegylated doxorubicin plus vinorelbine combination as first-line chemotherapy for metastatic breast cancer in elderly women > or = 65 years of age.
Addeo R; Faiola V; Guarrasi R; Montella L; Vincenzi B; Capasso E; Cennamo G; Rotundo MS; Tagliaferri P; Caraglia M; Del Prete S
Cancer Chemother Pharmacol; 2008 Jul; 62(2):285-92. PubMed ID: 17922275
[TBL] [Abstract][Full Text] [Related]
46. Pegylated liposomal doxorubicin in combination with vinorelbine as salvage treatment in pretreated patients with advanced breast cancer: a multicentre phase II study.
Ardavanis A; Mavroudis D; Kalbakis K; Malamos N; Syrigos K; Vamvakas L; Kotsakis A; Kentepozidis N; Kouroussis C; Agelaki S; Georgoulias V;
Cancer Chemother Pharmacol; 2006 Dec; 58(6):742-8. PubMed ID: 16718470
[TBL] [Abstract][Full Text] [Related]
47. A phase I clinical and pharmacological study evaluating vinflunine in combination with doxorubicin as first line treatment in metastatic breast cancer.
Zaman K; Durando X; Baurain JF; Humblet Y; Mazzeo F; Bostnavaron M; Meheust N; Monnoyer-Favrel S; Machiels JP; Bauer J
Breast Cancer Res Treat; 2011 Jun; 127(3):689-96. PubMed ID: 21442199
[TBL] [Abstract][Full Text] [Related]
48. Vinflunine: review of a new vinca alkaloid and its potential role in oncology.
Ng JS
J Oncol Pharm Pract; 2011 Sep; 17(3):209-24. PubMed ID: 20584744
[TBL] [Abstract][Full Text] [Related]
49. Vinflunine for the treatment of breast cancer.
Gourmelon C; Bourien H; Augereau P; Patsouris A; Frenel JS; Campone M
Expert Opin Pharmacother; 2016 Sep; 17(13):1817-23. PubMed ID: 27484180
[TBL] [Abstract][Full Text] [Related]
50. Vinflunine: drug safety evaluation of this novel synthetic vinca alkaloid.
Schutz FA; Bellmunt J; Rosenberg JE; Choueiri TK
Expert Opin Drug Saf; 2011 Jul; 10(4):645-53. PubMed ID: 21524237
[TBL] [Abstract][Full Text] [Related]
51. Vinflunine: clinical perspectives of an emerging anticancer agent.
Yun-San Yip A; Yuen-Yuen Ong E; Chow LW
Expert Opin Investig Drugs; 2008 Apr; 17(4):583-91. PubMed ID: 18363522
[TBL] [Abstract][Full Text] [Related]
52. Vinflunine in the treatment of advanced urothelial cancer: clinical evidence and experience.
Gerullis H; Wawroschek F; Köhne CH; Ecke TH
Ther Adv Urol; 2017 Jan; 9(1):28-35. PubMed ID: 28042310
[TBL] [Abstract][Full Text] [Related]
53.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
54.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
55.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
56.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
57.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
58.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
59.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
